Royal Bank Of Canada Dbv Technologies S.A. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.75 - $0.95 $38 - $48	-51 Reduced 60.0%	34 $0
Q4 2023 Feb 14, 2024	SELL	$0.7 - $1.33 $53 - $101	-76 Reduced 47.2%	85 $0
Q3 2023 Nov 14, 2023	SELL	$1.3 - $1.88 $239 - $345	-184 Reduced 53.33%	161 $0
Q2 2023 Aug 14, 2023	SELL	$1.42 - $2.23 $526 - $827	-371 Reduced 51.82%	345 $0
Q1 2023 May 15, 2023	BUY	$1.28 - $1.73 $108 - $147	85 Added 13.47%	716 $1,000
Q4 2022 Feb 14, 2023	BUY	$1.16 - $1.8 $388 - $603	335 Added 113.18%	631 $0
Q3 2022 Nov 14, 2022	BUY	$1.77 - $2.76 $341 - $532	193 Added 187.38%	296 $0
Q2 2022 Aug 15, 2022	BUY	$1.15 - $3.25 $60 - $172	53 Added 106.0%	103 $0
Q1 2022 May 16, 2022	SELL	$1.22 - $1.77 $610 - $885	-500 Reduced 90.91%	50 $0
Q4 2021 Feb 14, 2022	BUY	$1.39 - $5.58 $695 - $2,790	500 Added 1000.0%	550 $1,000
Q3 2021 Nov 15, 2021	SELL	$4.71 - $5.92 $193 - $242	-41 Reduced 45.05%	50 $0
Q2 2021 Aug 16, 2021	BUY	$5.32 - $6.53 $484 - $594	91 New	91 $0

253K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $128M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.